UroGen Pharma Q3 revenue misses expectations on JELMYTO decline
URGN•UroGen Pharma reported Q3 revenue of $89.001 million, below the $89.92 million consensus, as JELMYTO revenue declined. The company lowered its 2026 JELMYTO revenue guidance to about $90 million from $97 million to $101 million.
1. Quarterly results
UroGen Pharma’s Q3 revenue rose year over year to $89.001 million, missing the $89.92 million analyst consensus. Its net loss narrowed year over year to $1.46 million, also missing expectations for net income of $7.11 million.
2. Revenue and outlook
ZUSDURI revenue grew 35% quarter over quarter, which the company said was driven by increased repeat utilization, broader community adoption and physician engagement. JELMYTO revenue fell due to a one-time CMS adjustment and ongoing competitive clinical trial enrollment affecting patient starts. UroGen lowered its 2026 JELMYTO revenue guidance to about $90 million from $97 million to $101 million, and expects 2026 operating expenses of $260 million to $270 million, toward the upper end of the range.
